Promises and challenges of personalized medicine to guide ARDS therapy

Abstract Identifying new effective treatments for the acute respiratory distress syndrome (ARDS), including COVID-19 ARDS, remains a challenge. The field of ARDS investigation is moving increasingly toward innovative approaches such as the personalization of therapy to biological and clinical sub-ph...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Katherine D. Wick, Daniel F. McAuley, Joseph E. Levitt, Jeremy R. Beitler, Djillali Annane, Elisabeth D. Riviello, Carolyn S. Calfee, Michael A. Matthay
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Acute respiratory distress syndrome Acute lung injury Personalized medicine COVID-19 Clinical trials Medical emergencies. Critical care. Intensive care. First aid RC86-88.9
Acceso en línea:	https://doaj.org/article/2c6c7098eba946a6be310dfce60d01e8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2c6c7098eba946a6be310dfce60d01e8
record_format	dspace
spelling	oai:doaj.org-article:2c6c7098eba946a6be310dfce60d01e82021-11-28T12:03:49ZPromises and challenges of personalized medicine to guide ARDS therapy10.1186/s13054-021-03822-z1364-8535https://doaj.org/article/2c6c7098eba946a6be310dfce60d01e82021-11-01T00:00:00Zhttps://doi.org/10.1186/s13054-021-03822-zhttps://doaj.org/toc/1364-8535Abstract Identifying new effective treatments for the acute respiratory distress syndrome (ARDS), including COVID-19 ARDS, remains a challenge. The field of ARDS investigation is moving increasingly toward innovative approaches such as the personalization of therapy to biological and clinical sub-phenotypes. Additionally, there is growing recognition of the importance of the global context to identify effective ARDS treatments. This review highlights emerging opportunities and continued challenges for personalizing therapy for ARDS, from identifying treatable traits to innovative clinical trial design and recognition of patient-level factors as the field of critical care investigation moves forward into the twenty-first century.Katherine D. WickDaniel F. McAuleyJoseph E. LevittJeremy R. BeitlerDjillali AnnaneElisabeth D. RivielloCarolyn S. CalfeeMichael A. MatthayBMCarticleAcute respiratory distress syndromeAcute lung injuryPersonalized medicineCOVID-19Clinical trialsMedical emergencies. Critical care. Intensive care. First aidRC86-88.9ENCritical Care, Vol 25, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Acute respiratory distress syndrome Acute lung injury Personalized medicine COVID-19 Clinical trials Medical emergencies. Critical care. Intensive care. First aid RC86-88.9
spellingShingle	Acute respiratory distress syndrome Acute lung injury Personalized medicine COVID-19 Clinical trials Medical emergencies. Critical care. Intensive care. First aid RC86-88.9 Katherine D. Wick Daniel F. McAuley Joseph E. Levitt Jeremy R. Beitler Djillali Annane Elisabeth D. Riviello Carolyn S. Calfee Michael A. Matthay Promises and challenges of personalized medicine to guide ARDS therapy
description	Abstract Identifying new effective treatments for the acute respiratory distress syndrome (ARDS), including COVID-19 ARDS, remains a challenge. The field of ARDS investigation is moving increasingly toward innovative approaches such as the personalization of therapy to biological and clinical sub-phenotypes. Additionally, there is growing recognition of the importance of the global context to identify effective ARDS treatments. This review highlights emerging opportunities and continued challenges for personalizing therapy for ARDS, from identifying treatable traits to innovative clinical trial design and recognition of patient-level factors as the field of critical care investigation moves forward into the twenty-first century.
format	article
author	Katherine D. Wick Daniel F. McAuley Joseph E. Levitt Jeremy R. Beitler Djillali Annane Elisabeth D. Riviello Carolyn S. Calfee Michael A. Matthay
author_facet	Katherine D. Wick Daniel F. McAuley Joseph E. Levitt Jeremy R. Beitler Djillali Annane Elisabeth D. Riviello Carolyn S. Calfee Michael A. Matthay
author_sort	Katherine D. Wick
title	Promises and challenges of personalized medicine to guide ARDS therapy
title_short	Promises and challenges of personalized medicine to guide ARDS therapy
title_full	Promises and challenges of personalized medicine to guide ARDS therapy
title_fullStr	Promises and challenges of personalized medicine to guide ARDS therapy
title_full_unstemmed	Promises and challenges of personalized medicine to guide ARDS therapy
title_sort	promises and challenges of personalized medicine to guide ards therapy
publisher	BMC
publishDate	2021
url	https://doaj.org/article/2c6c7098eba946a6be310dfce60d01e8
work_keys_str_mv	AT katherinedwick promisesandchallengesofpersonalizedmedicinetoguideardstherapy AT danielfmcauley promisesandchallengesofpersonalizedmedicinetoguideardstherapy AT josephelevitt promisesandchallengesofpersonalizedmedicinetoguideardstherapy AT jeremyrbeitler promisesandchallengesofpersonalizedmedicinetoguideardstherapy AT djillaliannane promisesandchallengesofpersonalizedmedicinetoguideardstherapy AT elisabethdriviello promisesandchallengesofpersonalizedmedicinetoguideardstherapy AT carolynscalfee promisesandchallengesofpersonalizedmedicinetoguideardstherapy AT michaelamatthay promisesandchallengesofpersonalizedmedicinetoguideardstherapy
_version_	1718408190057512960

Promises and challenges of personalized medicine to guide ARDS therapy

Ejemplares similares